Business Wire

ONE-TRADING

Share
One Trading Secures Landmark Regulatory Approval for European Crypto Derivatives Trading

One Trading, a leading European crypto-asset exchange, has been granted an Organised Trading Facility (OTF) License by the Dutch financial market regulator. This license establishes One Trading as a MiFID II trading venue and marks a significant milestone in the company's multi-year journey with the Dutch Financial Markets Authority (AFM) and the Dutch Central Bank (DNB) to revolutionize the trading of derivatives and bring crypto futures onshore in the EU.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729953947/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joshua Barraclough - Founder and CEO of One Trading (Photo: Business Wire)

Transforming Derivatives Trading in Europe

With the new license, One Trading becomes the only perpetual futures trading venue in the EU and the first cash-settled perpetuals platform in Europe, including the UK. This approval establishes One Trading as the first regulated derivatives exchange in Europe accessible to retail clients.

In addition, One Trading is onshoring crypto derivatives as “traded on a trading venue” instruments, further enhancing the regulatory framework and security for European customers. The products that One Trading is rolling out are the modern alternative to products provided by traditional futures venues such as the CME or Eurex, but are simpler, more precise, and far more capital efficient than traditionally cleared derivatives such as dated futures.

Innovative and Proprietary Technology

One Trading's technical implementation of perpetual futures sets it apart as the first trading venue in the world to offer real-time (<1-minute tick level) settlement of all derivatives positions, 24/7 on all markets. This groundbreaking capability complements the proprietary technology already developed to provide the fastest and most scalable spot trading venue globally. One Trading’s technology seamlessly integrates custody and settlement on DLT, making it the first EU venue to allow the use of crypto-assets as collateral for trading regulated financial instruments.

Comprehensive and Integrated Clearing and Settlement

As the only regulated exchange that integrates derivatives product creation and trading without the need for external clearing, One Trading offers an unmatched suite of services which are all directly available to professional and retail clients. With DLT infrastructure mobilising collateral t+0 and 24/7, One Trading challenges existing financial market infrastructure as the first to eliminate costly post-trade processes in favour of a clear, safe, and robust structure focused on helping all clients get the exposures they want - and nothing more. This integrated approach is brought to life in a highly regulated environment by use of leading technology, making it a unique and hard-to-replicate model within MiFID II.

Joshua Barraclough, Founder and CEO of One Trading commented, "We are thrilled to have achieved this milestone, which represents the culmination of years of hard work and innovation. The long-term vision of the company is to enable all customer types to go long or short on any asset, use any asset as collateral, settle everything instantly, and perpetually roll contracts. Our team has been dedicated to developing a platform that not only meets but exceeds the highest regulatory standards. With this licence, we are well positioned to introduce new regulated products and offer institutional-grade solutions to all customer types starting with BTC and ETH products where no onshore EU regulated venue currently exists. This is just the beginning of our journey to redefine the landscape of digital asset and traditional security trading."

A Significant Achievement in Regulatory Approvals

Receiving the first new Organised Trading Facility license granted in the EU in the past three years underscores the rigorous standards One Trading achieved. This reflects the company's innovative approach and trusted leadership, as well as its dedication to reshaping how regulated financial instruments are traded in the digital age.

General Counsel Mario Hoessl-Neumann added: “It has been a great experience working very closely with the Dutch regulators throughout much of this process, and we appreciate their vision and foresight to bring a new market structure for regulated derivatives trading to the EU. By launching a novel form of financial instruments with purpose-built tech and the seamless integration of DLT-based assets on the One Trading platform, we are not just providing European clients with the first onshore alternative to unregulated exchanges. More fundamentally, we are complementing - and in some important ways replacing - traditional structures for how regulated derivatives such as futures are traded. It has always been a core value to us to maintain equal capabilities for professional and retail clients, and it is great to see that we are now first in Europe to bring to life a trading venue that truly works for all.

One Trading has been advised on its license application by A&O Shearman (Alexander Behrens) and Freshfields Bruckhaus Deringer (Daphne van der Houwen and Stephan Pachinger).

About One Trading

One Trading is a European digital asset exchange headquartered in the Netherlands. The company is committed to providing a secure, fast, and scalable platform for trading crypto-assets and derivatives. With a focus on innovation and regulatory compliance, One Trading aims to set new standards in the industry and offer unparalleled services to its customers. For more information, please visit our website, X, or LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240729953947/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye